Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults - Wikidata - wikimedia - TriplyDB

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

http://www.wikidata.org/entity/Q36172965

about

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging.Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1.Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.Mucosal immunology of HIV infection.Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.Development of prophylactic vaccines against HIV-1.Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.The role of follicular helper CD4 T cells in the development of HIV-1 specific broadly neutralizing antibody responses

P2860

Q28741103-30FEE94A-047E-4CD6-A199-97B90518D5E4 Q30234577-2F60707F-C6CF-4C54-A05F-E23DBE2A480D Q30528889-23885D6F-79F3-4CA8-A7FF-323F98D76EB1 Q33803963-4277D7A1-DB09-4583-BA09-4C6FA8931BEE Q34240204-3116E38C-07A2-4D68-82CF-CDD1441D815C Q35388181-D16F1FFB-411F-4959-8716-74E648A2D765 Q35762443-CFE4EC43-CBA8-414D-8144-C9D7E12BA759 Q35774494-D558EDA7-7C97-4417-95A0-AECDDDEB4A90 Q36957775-BFB1AB91-DE76-4BD8-ACE0-442C585BC96C Q36971813-17AF7867-1058-4B63-A688-17BCA4A0D4EC Q37042563-3DA12D8D-E6CF-4176-AF11-D51629014699 Q37277825-2E209AD7-FF9B-4BA3-A98F-AEEC730DB10B Q57170667-8034CD56-C6A8-4D43-BAAF-D20A92E86190

P2860

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

http://www.wikidata.org/entity/Q36172965

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Safety and Immunogenicity of t ...... hase 1 Study of Healthy Adults

@ast

Safety and Immunogenicity of t ...... hase 1 Study of Healthy Adults

@en

type

label

Safety and Immunogenicity of t ...... hase 1 Study of Healthy Adults

@ast

Safety and Immunogenicity of t ...... hase 1 Study of Healthy Adults

@en

prefLabel

Safety and Immunogenicity of t ...... hase 1 Study of Healthy Adults

@ast

Safety and Immunogenicity of t ...... hase 1 Study of Healthy Adults

@en

P1433

Q36172965-2893B793-498A-4936-827B-0953143988DA

P1476

Q36172965-1AC6A77B-A158-452B-9844-7E9E29078737

P2093

Q36172965-08C44CEA-66E6-4F69-9D9A-5E86AAF96092

Q36172965-0929A04E-4036-4AB9-A1F5-4D3DFD970E74

Q36172965-18A298E7-F48E-4D23-8FAE-ED0B3DD4D1DA

Q36172965-19CE6DB3-BFAD-462B-B249-5B700F3E7991

Q36172965-19CF1365-3E48-4C45-82E2-4107525B3830

Q36172965-2E384156-DBD6-4D81-A8F4-B11DD2A53B79

Q36172965-300AAC0B-4C2D-4BA5-AF63-92D111E6EF32

Q36172965-38FB9F06-15D4-4294-B942-88F16804A2AC

Q36172965-5236A28B-7240-41FF-8DBB-8C41CAF3262F

Q36172965-5C4A71FB-560A-44C2-9F48-F2A6894B7D2D

P2860

Q36172965-00EB9432-AFEC-4323-8229-FAF4A7AABC48

Q36172965-03367CFB-355A-41CB-B53A-F182301B9D1E

Q36172965-05E852F4-B3A2-41AD-A857-14451C6369C9

Q36172965-06EE6312-CEB5-44E5-8163-332E2F895AA4

Q36172965-0C9AF489-EFCF-4AC1-A60A-7077FCD72182

Q36172965-12AEAF8E-96D8-44A3-A22E-EF465EA91944

Q36172965-14FA94C7-1905-4C1B-96B9-3A824F88001A

Q36172965-1648E339-B4AC-4D00-99D6-338C1CF0E57A

Q36172965-1A43BFE2-EBCC-4A1C-9621-77AB2FC2D173

Q36172965-1D7D4F54-435B-43B9-9FA6-4AB29A2A4E97

P304

Q36172965-74B354FC-EFEA-46D7-86D6-FD55379B5007

P31

Q36172965-AB71C9F4-10C5-445E-AD42-94AE5D71DDC0

P356

Q36172965-84FFC079-14EA-4A8E-BD74-0F279D57B635

P407

Q36172965-E0E0D32E-D9B0-4837-8DB7-C280FE1EDC61

P433

Q36172965-E5E0A0C1-19FE-41CB-81C6-F2617A7FB33F

P478

Q36172965-93829FC1-7704-4A43-8524-829882DD12EC

P50

Q36172965-65D65D62-9B72-49F4-B411-92B4A4A12D4F

Q36172965-767740C5-1593-4343-B506-4DBDEF347943

Q36172965-91A00EE3-6CCA-47DF-854F-31CD317E7D9A

P577

Q36172965-86EE4B9E-25A2-4CCA-89D3-ABB82256286C

P698

Q36172965-276901C4-26FE-496F-A962-FD8F9C010C7E

P921

Q36172965-15908686-F1F3-427C-94C2-92645E6785A1

Q36172965-689F515E-4AE2-42C9-9610-2C8E6C4BD2B8

Q36172965-BECAEC2F-3A92-418E-BD34-71E64CD6E937

P932

Q36172965-DBD4D131-7B19-40D3-8049-D49BCCA5B86D

P356

P1433

AIDS Research and Human Retroviruses

P1476

Safety and Immunogenicity of t ...... hase 1 Study of Healthy Adults

@en

P2093

Ann Duerr

http://www.w3.org/2001/XMLSchema#string

Danilo Casimiro

http://www.w3.org/2001/XMLSchema#string

Devan V Mehrotra

http://www.w3.org/2001/XMLSchema#string

Erin Quirk

http://www.w3.org/2001/XMLSchema#string

Fay Dicandilo

http://www.w3.org/2001/XMLSchema#string

Jorge Sanchez

http://www.w3.org/2001/XMLSchema#string

Katherine Turner

http://www.w3.org/2001/XMLSchema#string

Lisa Kierstead

http://www.w3.org/2001/XMLSchema#string

Michael N Robertson

http://www.w3.org/2001/XMLSchema#string

Michelle Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial

Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy.

Human resources requirements for highly active antiretroviral therapy scale-up in Malawi.

Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.

Use of the false discovery rate for evaluating clinical safety data.

P304

557-567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/AID.2010.0151

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Jean William Pape

P577

2010-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20854108

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

3422055

http://www.w3.org/2001/XMLSchema#string